A randomized,phase 3 trial of naltrexone SR/bupropion SR on weight and obesity‐related risk factors (COR‐II) |
| |
| Authors: | Louis Aronne Domenica Rubino Christopher Still Holly Wyatt Colleen Burns Dennis Kim Eduardo Dunayevich for the COR‐II Study Group |
| |
| Institution: | 1. Weill Cornell Medical College, New York, New York, USA;2. Washington Center for Weight Management, Arlington, Virginia, USA;3. Geisinger Health Care System, Danville, Pennsylvania, USA;4. University of Colorado Denver, Denver, Colorado, USA;5. Orexigen Therapeutics, Inc., La Jolla, California, USA |
| |
| Abstract: | Objective: To examine the effects of naltrexone/bupropion (NB) combination therapy on weight and weight‐related risk factors in overweight and obese participants. Design and Methods: CONTRAVE Obesity Research‐II (COR‐II) was a double‐blind, placebo‐controlled study of 1,496 obese (BMI 30‐45 kg/m2) or overweight (27‐45 kg/m2 with dyslipidemia and/or hypertension) participants randomized 2:1 to combined naltrexone sustained‐release (SR) (32 mg/day) plus bupropion SR (360 mg/day) (NB32) or placebo for up to 56 weeks. The co‐primary endpoints were percent weight change and proportion achieving ≥5% weight loss at week 28. Results: Significantly (P < 0.001) greater weight loss was observed with NB32 versus placebo at week 28 (?6.5% vs. ?1.9%) and week 56 (?6.4% vs. ?1.2%). More NB32‐treated participants (P < 0.001) experienced ≥5% weight loss versus placebo at week 28 (55.6% vs. 17.5%) and week 56 (50.5% vs. 17.1%). NB32 produced greater improvements in various cardiometabolic risk markers, participant‐reported weight‐related quality of life, and control of eating. The most common adverse event with NB was nausea, which was generally mild to moderate and transient. NB was not associated with increased events of depression or suicidality versus placebo. Conclusion: NB represents a novel pharmacological approach to the treatment of obesity, and may become a valuable new therapeutic option. |
| |
| Keywords: | |
|
|
